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The prevalence of comorbid diabetes and depression is high, espe-
cially in low-income Hispanic or Latino patients. The complex
mix of factors in safety-net care systems impedes the adoption of
evidence-based collaborative depression care and results in per-
sistent disparities in depression outcomes. The Diabetes–Depres-
sion Care-Management Adoption Trial examined whether the col-
laborative  depression  care  model  is  an  effective  approach  in
safety-net clinics to improve clinical care outcomes of depression
and diabetes.
Methods
A sample of 964 patients with diabetes from 5 safety-net clinics
were enrolled in a quasi-experimental study that included 2 arms:
usual care, in which primary medical providers and staff trans-
lated and adopted evidence-based depression care; and supportive
care, in which providers of a disease management program de-
livered protocol-driven depression care. Because the study design
established individual treatment centers as separate arms, we cal-
culated propensity scores that interpreted the probability of treat-
ment assignment conditional on observed baseline characteristics.
Primary outcomes were 5 depression care outcomes and 7 dia-
betes care measures. Regression models with propensity score co-
variate adjustment were applied to analyze 6-month outcomes.
Results
Compared with usual care, supportive care significantly decreased
Patient Health Questionnaire-9 scores, reduced the number of pa-
tients with moderate or severe depression, improved depression re-
mission, increased satisfaction in care for patients with emotional
problems, and significantly reduced functional impairment.
Conclusion
Implementing collaborative depression care in a diabetes disease
management program is a scalable approach to improve depres-
sion outcomes and patient care satisfaction among patients with
diabetes in a safety-net care system.
Introduction
Diabetes is a chronic, lifelong illness that increases the risk of ill-
ness and death (1). Diabetes doubles the risk of comorbid depres-
sion (2,3). The high prevalence of depression with concurrent dia-
betes increases patient disability and need for social support and
negatively affects treatment efficacy, medication adherence, self-
care management, patient–physician communication, and quality
of life (4–6). Furthermore, Hispanics and Latinos have a higher
prevalence of diabetes than non-Hispanic or non-Latino whites
(7),  and patients with comorbid depression and diabetes are at
greater risk of functional disability, poor health service use, and
death (8,9).
Primary care depression treatment is effective among low-income,
racial and ethnic minority populations (10–13). When collaborat-
ive care is adopted both by patients and providers, the treatment of
depression becomes effective and cost-efficient (14). However, the
complex mix of patient, provider, and health system factors in
safety-net care systems impedes the adoption of evidence-based
collaborative depression care and results in persistent disparities in
depression outcomes.
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The  Diabetes–Depression  Care-Management  Adoption  Trial
(DCAT) examined a safety-net disease management program for
depression prevention, screening, surveillance, and intervention
(15). There are many single-disease management programs, in-
cluding many for diabetes. These programs provide the infrastruc-
ture of care teams and patient registries for implementing collabor-
ative depression care.  Supportive care programs that expand a
single-disease focus to concurrently address the common comor-
bid condition of depression have the potential to better meet pa-
tient needs and improve clinical outcomes (14,16,17).
We examined the ability of a supportive care approach to fill gaps
in the implementation of depression care and facilitate optimal ad-
aptive depression care management in safety-net primary care set-
tings. We expected that DCAT would find a supportive care pro-
gram improves 6-month clinical outcomes of both diabetes and de-
pression.
Methods
Overall design, intervention, and hypothesis
The DCAT team conducted a quasi-experimental  trial  that  ex-
amined the effects of implementing depression monitoring in a
diabetes disease management program for low-income urban pop-
ulations in the Los Angeles County Department of Health Ser-
vices (DHS) Ambulatory Care Network, the second-largest safety-
net care system in the United States. Before DCAT, DHS had a
diabetes  disease  management  program with  nurse-driven  and
physician-supervised care management for high-risk or high-ser-
vice-use patients. DHS applies evidence-based diabetes care man-
agement components and uses structured tools (case management,
patient education and self-management support, care coordination,
depression screening and physician notification, an electronic dis-
ease registry, and integrated clinical decision support systems) to
deliver more than 80% of the care by nurses under protocol and
was the model for the supportive care group. These tools support
clinical assessment and decisions in a limited care-management
period of 6 months. The integration of team staff, including physi-
cians, nurse practitioners, nurses, and social workers, provided an
intensive care model with strict guidelines for follow-up and mon-
itoring of diabetes symptoms and comorbid risks, such as depres-
sion. Participants received weekly telephone calls from care team
members  and  were  seen  by  nurses  and  social  workers  who
provided comprehensive team-based care to improve disease man-
agement and quality of care.
During implementation of  DCAT, from October  2011 to  May
2013, diabetes disease management was supplemented with peri-
odic screening and monitoring of depression symptoms with the
Patient Health Questionnaire 9-item scale (PHQ-9), a standard tool
in each clinic’s disease registry, and the DHS depression care pro-
tocol and treatment guideline. The program also designated a so-
cial  worker  to  provide  problem-solving therapy,  an  evidence-
based treatment of depression. All care providers were offered
training in problem-solving therapy via a 1-day workshop; they
were also trained in the collaborative depression care model and
adaptive treatment approach via 1 of 3 webinars.
This study involved 5 DHS primary care clinics, selected by DHS
leaders on the basis of criteria that reflected geographic and dia-
betes care model diversity. The usual care group included 2 com-
munity clinics that represented standard clinical practice, in which
primary medical providers and their staff translated and adopted
evidence-based depression care. The supportive care study group
included 2 care teams from the DHS diabetes disease manage-
ment program. These teams practiced in 2 community clinics and
1  hospital-based  outpatient  clinic.  We  hypothesized  that  at  6
months after enrollment in the study, patients who received the
diabetes supportive care would have improved depression and dia-
betes outcomes compared with patients receiving usual care.
Population characteristics and eligibility
Patients were recruited from 5 DHS primary care clinics. The pa-
tients were predominantly low-income, low-literacy, middle-aged,
Spanish-speaking Hispanic or Latino women who had been dia-
gnosed with diabetes for more than 5 years. Approximately one-
third of participants were depressed, and approximately one-third
of the patients were men.
Patients were eligible for the study if they were aged 18 years or
older  with  type  2  diabetes,  had  a  working  telephone  number,
spoke English or Spanish, and read and understood the consent
form. Patients were ineligible for the trial if they presented with
baseline acute suicidal ideation (as measured by PHQ-9, item 9),
cognitive impairment (Short Portable Mental Status Questionnaire
scores less than 5) (18), alcohol abuse (2 or more CAGE items
from a quantity–frequency index, and patient perceptions of sub-
stance  use)  (19),  or  if  they  had  recently  used  lithium or  anti-
psychotic medication. Patients were not required to have depres-
sion to be eligible for the study because DCAT addressed the elev-
ated risk of depression among patients with diabetes by testing a
care approach that incorporates depression screening, symptom
monitoring, and treatment follow-up for diabetes patients.
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Recruitment
Approval was obtained from the University of Southern Califor-
nia and the Los Angeles Biomedical Research Institute human
subjects review boards. The enrollment period was from April
2011 to May 2012 in the 5 study clinics. Patients with type 2 dia-
betes were identified for recruitment from database and clinic re-
cords. Patients provided verbal consent during study eligibility
screening to bilingual research assistants. Of the 1,704 patients
screened, 1,066 (63%) were women and 638 (37%) were men.
Men had a significantly lower enrollment rate than women (83%
vs 88%, respectively; P = .003), which was associated with poor
alcohol use scores (5% vs 1%, respectively). A total of 964 dia-
betes patients  (86% of patients  screened) provided written in-
formed consent and completed a structured baseline interview that
included  both  PHQ-9  (scores  range  from 0–27,  where  higher
scores indicate worse depression) and Hopkins Symptom Check-
list-20 depression symptom assessments (individual items scored
0–4,  where higher  scores  indicate  worse depression)  (Figure).
After excluding 87 participants with missing data, the baseline
sample had 877 patients: 416 patients in the usual care group and
461 patients in the supportive care group. Patient and family edu-
cational materials concerning depression, including a comic book
fotonovela (20) designed for patients and family members with
low health literacy, were provided to all study patients in Spanish
or English by bilingual study recruiters. The study clinic physi-
cians were notified of the baseline depression screening results for
patients whose PHQ-9 scores were 10 or higher or who exhibited
suicidal ideation (score greater than 1 for item 9 of PHQ-9). Parti-
cipants received no monetary incentive for the study enrollment
and baseline assessment. However, they did receive a $10 gift card
for each follow-up assessment they completed. The study clinics
participated in the study pro bono.
Figure.  Consolidated Standards of  Reporting Trial  (CONSORT)  diagram of
sample of study participants drawn from type 2 diabetes patients identified in
database and clinic records at safety-net clinics where they sought treatment,
Los Angeles County,  California, 2011–2013. Propensity scores were used to
determine the probability of treatment assignment conditional on observed
baseline characteristics.  Some patients were excluded because they were
temporarily unavailable (eg, they were out of the state or country, it was not a
good time to talk, their telephone was disconnected).
 
Outcome measures
All subjects received comprehensive assessments at baseline and
at 6, 12, and 18 months by independent English–Spanish bilingual
interviewers. Primary outcomes included 5 depression outcomes
and 7 diabetes care measures (including satisfaction with care and
disability reduction) (Table 1).
Sample size calculation
The target sample size was based on power analysis for 2 primary
outcomes: reduction of prevalence of major depression (PHQ-9
score ≥10) and depression remission (PHQ-9 score ≤8 with a re-
duction  ≥50%  for  patients  with  major  depressive  disorder  at
baseline). Power analyses were conducted using nQuery (Statistic-
al Solutions) to estimate effect sizes of the treatment with preinter-
vention and postintervention comparisons and longitudinal statist-
ical approaches for repeated measures comparing the trend of de-
pression-related outcomes in the DCAT study. The calculations
assumed an α level of .05 and a power of .80. With the assump-
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tion that attrition rates would be less than 20% for patients at each
6-month follow-up assessment — up to 18 months for preinterven-
tion and postintervention comparisons — a sample size of 51 pa-
tients with depression in each study group would allow the detec-
tion of a small effect size of less than .01. A previous trial in 2008
of the Multifaceted Depression and Diabetes Program established
that 25% to 30% of diabetes patients also experience depression
(21);  for  DCAT,  we  added  a  25%  cushion  for  differences  in
baseline characteristics because of the quasi-experimental trial
design. Therefore, DCAT required a sample size of approximately
500 type 2 diabetes patients in each study group.
Statistical methods
Initial statistical tests were performed to assess differences in dif-
ferences (DID). However, because the study design defined indi-
vidual treatment centers as separate arms, we aimed to improve
statistical testing by calculating propensity scores to interpret the
probability  of  treatment  assignment  conditional  on  observed
baseline characteristics. Both tests were performed with assump-
tions of P ≤ .05. A multinomial logistic regression model was used
to estimate the propensity score; the model used study group as the
dependent variable and all 27 measured baseline characteristics as
the independent variables. The baseline characteristics were 1)
age, 2) sex, 3) preferred language, 4) body mass index, 5) educa-
tion  level,  6)  employment  status,  7)  economic  status,  8)  total
stressor number, 9) sum of the stress level, 10) predicted future
health cost, 11) age at onset of diabetes, 12) insulin use, 13) Med-
ical Outcomes Study Short Form-12 Health Survey (SF-12) phys-
ical score (scored 0–100, where higher scores indicate a higher
level of physical health), 14) SF-12 mental score (scored 0–100,
where higher scores indicate a higher level of mental health), 15)
number of diabetes complications, 16) Whitty-9 diabetes symp-
toms scale score (scored 1–5, where higher scores indicate more
severe diabetes), 17) diabetes emotional burden, 18) diabetes regi-
men distress, 19) mean Toolbert diabetes self-care score (scored
0–7, where higher scores indicate better diabetes self-care), 20)
PHQ-9 score (scored 0–27, where higher scores indicate worse de-
pression), 21) Brief Symptom Inventory total score (scored 0–24,
where higher scores indicate worse anxiety) , 22) mean Sheehan
Disability Scale score (scored 0–10, where higher scores indicate
more significant functional impairment), 23) dysthymia, 24) previ-
ous diagnosis of major depressive disorder, 25) chronic pain, 26)
overall patient satisfaction, and 27) glycated hemoglobin (A1c)
value. We subsequently checked the distribution of the estimated
propensity scores because between-group comparisons would be
suspect if there had been substantial separation between treatment
arms; the propensity score method is  a more conservative and
parsimonious  statistical  modeling  method  for  nonrandomized
study samples (22).
Comparative treatment effects were estimated using linear or lo-
gistic regression models featuring outcomes at 6 months as the de-
pendent variable; the independent variables were study group, care
team, outcome variable at baseline, estimated propensity scores,
insulin use, A1c, age, sex, and preferred language. Regression that
includes estimated propensity scores as covariates is an effective
tool to adjust sample biases in observational or quasi-experiment-
al studies (23). The coefficients of study groups predicted compar-
ative treatment effects. Three care team variables were used to ad-
just for differences among providers. Analyses were performed by
using SAS version 9.1 (SAS Institute, Inc).
Results
Population characteristics
The DCAT study enrolled 964 low-income, predominantly His-
panic or Latino patients with diabetes to test  and compare the
translational models of depression care management. Of these pa-
tients, 484 were in the usual care group and 480 in the supportive
care group.
Because DCAT used a quasi-experimental design comparing study
groups, we first examined whether major baseline characteristics
that could influence the outcome measures were balanced between
the study groups. There were no significant differences in baseline
PHQ-9 depression or SF-12 mental scores,  Sheehan Disability
Scale  ratings,  or  body  mass  index  in  pairwise  comparisons
between groups (Table 2).
Outcomes
The DID test with the main outcome variable of PHQ-9 change
score at 6 months was significant (P = .01). When adjusted for the
same covariates, DID and propensity score methods had consist-
ent results (P = .01 and P = .05, respectively).
Compared with usual care, supportive care significantly decreased
PHQ-9 scores (least squares mean [LSM] = 6.34, standard error
[SE] = 0.49 vs LSM = 5.08, SE = 0.48, respectively; P = .047), re-
duced the number of patients with moderate or severe depression
(a PHQ-9 score ≥10; P = .04), and improved depression remission
(P = .05) (Table 3). Supportive care also significantly improved
patient satisfaction with care for emotional problems (P = .01).
Scores on the Sheehan Disability Scale (P = .03) were signific-
antly lower in the supportive care group compared with the usual
care group. There were no significant differences between the 2
groups in terms of satisfaction with care, emotional distress among
patients with a baseline PHQ-9 score of 10 or more, cholesterol,
diabetes self-care, exercise, satisfaction with diabetes care, or A1c
levels.
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Discussion
Evidence-based collaborative depression care in a diabetes dis-
ease management program designed to reduce disparities in com-
bined diabetes and depression care represents an important and
valuable tool for future providers that may greatly improve over-
all care, cost, and effectiveness of health care delivery for under-
served  patients.  Our  findings  indicated  that  supportive  care
through depression monitoring can improve diabetes and depres-
sion outcomes in the second-largest US safety-net health system.
Patients enrolled in the supportive care group had significantly de-
creased PHQ-9 scores, reduced levels of moderate or severe de-
pression, and improved depression remission. Additionally, pa-
tients enrolled in the supportive care group had significantly de-
creased values on the Sheehan Disability Scale. Although some
aspects of care were not significantly different between groups, the
ability to target depression as an outcome in a group of patients
with diabetes is a potentially life-altering improvement for each
patient. Many studies have outlined the risk of worsening diabetes
outcomes in patients who also have depression (8,24). These risks
are amplified in patients who are unable to receive depression
management support in usual care, and these people are often low-
income minority patients (7,25). Although between-group changes
in A1c levels were not significant, the supportive care group did
have lower values. Perhaps an extended study (follow-up beyond
6 months) or a more intensive version of supportive care could
promote greater improvement in specific diabetes outcomes. Al-
ternatively, because study patients in the supportive care group
had been in the diabetes care management program for 3 months,
on average, before the DCAT intervention, diminished improve-
ments in outcomes may have resulted from previous program ef-
fects. However, it appears that the care received by the supportive
care group resulted in improvements in depression management
and may result from the strict guidelines of the diabetes manage-
ment program in terms of requisite number of visits and follow-up.
It may also be that the increased role of nurses and social workers
on the care team can provide additional quality and quantity of
care, allowing patients to focus on comorbid conditions such as
depression.
Applied on a large scale across many different chronic diseases,
the integration of care for comorbid diseases could greatly im-
prove outcomes overall and help prevent worsening of chronic dis-
eases. Specifically, decreasing the prevalence of depression in can-
cer patients significantly improves quality of life and cancer out-
comes (10,12). Expanding methods to improve quality of life and
clinical outcomes for patients with diabetes, which affects more
than 285 million adults worldwide (26), is an additional step to
preventing chronic disease progression.
The main limitation of this study is that it was not randomized but
rather conducted across 5 DHS clinics as a quasi-experimental tri-
al. However, use of the propensity scores provided an analysis of
differences across clinics and suggested that there was no signific-
ant difference between sites. Nevertheless, differences across clin-
ics, patients, and providers must be considered for practical applic-
ation. Another potential limitation may be the focus on a predom-
inantly Hispanic or Latino population. Conversely, an important
aspect of the DCAT model was its focus on reducing disparities
among low-income minority patients in safety-net primary care
settings. The fact that continuous depression symptom assessment,
treatment monitoring, and relapse prevention may be difficult in
busy safety-net primary care practices may be another limitation;
additional methods may be necessary to ensure adoptability, cost-
effectiveness, and scalability. However, improvements in clinical
satisfaction and outcomes indicate that researchers should study
chronic  diseases  across  multiple  risks.  As such,  the  design of
DCAT diabetes-depression supportive care may be a tool to aid in
prevention efforts and care for all patients with chronic diseases.
Although some demographic and diabetes variables varied signi-
ficantly between the study groups, this was expected given that in
the quasi-experimental DCAT design, pretreatment differences are
more common than those expected from randomized experimental
design.  However, because participants were recruited from com-
munity clinics, results should be applicable to individuals not in-
volved in the study but who also receive community care.
Expanding diabetes disease management to support the incorpora-
tion of a collaborative depression care model may be an effective
approach to prevent the progression of chronic diseases. Imple-
menting this approach in an underserved population with a high
prevalence of diabetes may also have the added benefit of redu-
cing health disparities while improving clinical outcomes and fun-
damentally influencing primary care. Further research is required
to understand the full adaptability of the DCAT supportive care
model and its effect on lifetime clinical outcomes.
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Tables
Table 1. Primary Outcome Measures, Diabetes–Depression Care-Management Adoption Trial, Los Angeles, 2011–2013
Outcome Description
Depression
PHQ-9 A continuous variable that assesses severity of depression.
PHQ-9 ≥10 A dichotomous variable that assesses severity of depression. PHQ-9 ≥10 indicates
major depression. Higher scores indicate worse depression.
Depression remission A dichotomous variable that assesses effectiveness of treating patients with major
depression. Depression remission is defined as baseline PHQ-9 ≥10 and 6-month PHQ-
9 ≤8 with a reduction ≥50%.
Satisfaction in care with emotional
problems
Five-level score that assesses mental care satisfaction. Treated as continuous variable.
Satisfaction in care with emotional
problems for patients with baseline PHQ-
9 ≥10
Five-level score that assesses mental care satisfaction of patients with major
depression. Treated as continuous variable.
Diabetes
A1c value A continuous variable that assesses severity of diabetes. A1c value indicates the
average plasma glucose concentration over prolonged periods.
A1c tested A dichotomous variable that assesses the diabetes care process.
Total cholesterol A continuous variable that evaluates cholesterol levels and severity of diabetes.
Diabetes self-care Number of days per week of diabetes self-care. Treated as a continuous variable.
Exercise Number of days of exercise during the previous week.
Sheehan Disability Scale A self-report tool that assesses functional impairment in work or school, social, and
family life.
Satisfaction in diabetes care Five-level score that assesses diabetes care satisfaction. Treated as continuous
variable.
Abbreviations: PHQ-9, Patient Health Questionnaire-9; A1c, glycated hemoglobin.
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Table 2. Comparison of Baseline Characteristics of 964 Subjects Enrolled in Diabetes–Depression Care-Management Adoption Tri-
al, Los Angeles, 2011–2013
Characteristics Usual Care (n = 484) Supportive Care (n = 480) P Value
Demographics
Female, % 69 59 .002
Age, mean, y 55.0 52.1 <.001
Hispanic or Latino, % 94 83 <.001
Prefers Spanish, % 89 78 <.001
Diabetes
Age at onset of diabetes, mean, y 45.0 41.8 <.001
Uses insulin, % 26 63 <.001
Has diabetes complication, % 71 74 .32
Diabetes self-care, mean 4.00 4.75 <.001
Body mass index, mean, kg/m2 32.34 32.55 .66
Sheehan Disability Scale,a mean 2.24 2.13 .55
Depression and anxiety, mean score
Patient Health Questionnaire-9b 6.67 6.93 .50
Hopkins Symptom Checklist-20c 0.56 0.64 .08
Brief Symptom Inventoryd 1.35 1.30 .81
Functional status, Medical Outcomes Study Short Form-12, mean scoree
Physical 43.04 45.81 <.001
Mental 50.05 49.03 .23
a The Sheehan Disability Scale is scored from 0 to 10, where higher scores indicate more significant functional impairment.
b The Patient Health Questionnaire-9 is scored from 0 to 27, where higher scores indicate worse depression.
c Individual items on the Hopkins Symptom Checklist-20 are scored from 0 to 4, where higher scores indicate worse depression.
d The Brief Symptom Inventory is scored from 0 to 24, where higher scores indicate worse anxiety.
e The Medical Outcomes Study Short Form-12 is scored from 0 to 100, where higher scores indicate a higher level of physical health.
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PHQ-9 (higher scores indicate worse depression) 6.34 (0.49) 5.08 (0.48) .047
Satisfaction with emotional care (higher scores indicate greater
satisfaction)
3.24 (0.10) 3.64 (0.10) .01
Satisfaction with emotional care among patients with baseline PHQ-9
score ≥10 (higher scores indicate greater satisfaction)
3.18 (0.22) 3.59 (0.21) .19
Cholesterol, mg/dL 176.21 (5.24) 166.80 (4.98) .19
Diabetes self-care (days/week) 4.67 (0.13) 4.70 (0.12) .93
Exercise (days/week) 4.74 (0.28) 4.90 (0.27) .64
Sheehan Disability Scale (higher scores indicate greater disability) 3.21 (0.26) 2.60 (0.25) .03
Satisfaction with diabetes care (higher scores indicate greater satisfaction) 4.00 (0.09) 4.15 (0.09) .32
A1c value 7.95 (0.17) 7.79 (0.16) .17
Dichotomous Outcome Supportive vs Usual Care, OR (95% CI) P Value
PHQ-9 score ≥10 0.46 (0.23–0.90) .04
Depression remission 3.08 (1.01–9.45) .05
A1c tested 1.80 (0.88–3.68) .10
Abbreviations: LSM, least squares mean; SE, standard error; PHQ-9, Patient Health Questionnaire-9; A1c, glycated hemoglobin; OR, odds ratio; CI, confidence inter-
val.
a Both linear and logistic regression models were adjusted for study group, care team, outcome variable at baseline, propensity score, insulin use, A1c, age, sex,
and preferred language.
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